Please login to the form below
oral semaglutide
This page shows the latest oral semaglutide news and features for those working in and with pharma, biotech and healthcare.
Novo’s oral diabetes drug hits the mark again
The 26-week phase IIIa trial, also known as PIONEER 5, investigated oral semaglutide in 324 patients with type 2 diabetes and who have a kidney-impairment, a serious diabetes complication. ... in people with type 2 diabetes and moderate renal impairment,
Latest news
-
Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
The firm’s top R&D priority remains its once-daily oral formulation of Ozempic active ingredient semaglutide, which now has data from four of 10 phase III trials in diabetes ... The company thinks oral semaglutide could be a game-changer for the GLP-1
-
News: Charity criticises NHS England and Vertex over Orkambi access, Sema scores again, NodThera launched
This follows data released ahead of the congress which showed the as-yet-unapproved oral semaglutide outperformed market leading oral treatment, Merck &Co’s Januvia, as well as its own injectable ... Victoza. Oral semaglutide also outperformed
-
Novo’s diabetes pill defeats Merck’s Januvia in trial
Novo’ s diabetes pill defeats Merck’ s Januvia in trial. Oral semaglutide also outshines its best-selling diabetes injectable Victoza. ... A familiar story was told when oral semaglutide was compared with Novo’s best-selling diabetes blockbuster
-
Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1
Novo claimed approval for its own once-weekly GLP-1 drug – Ozempic (semaglutide) – towards the end of last year, and the new product made DKK 69m in its first few weeks ... to Trulicity, and is also making progress to filing its oral formulation of
-
Novo Nordisk’s semaglutide obesity trial hits the mark
Meanwhile, Novo has also just reported positive late-stage results with an oral formulation of semaglutide, setting it on a path to possible filing in 2019 and rounding out what some ... Obesity and the oral form play a big part in that view, but
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Oral biologics delivery still elusive
Novo Nordisk is also working with another specialist on oral delivery for protein drugs - Emisphere Technologies - that has applied its Eligen technology to develop an oral version of semaglutide, a ... rarely as once a quarter for example, which makes
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Director - Digital
-
Great salary and benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager, Healthcare Advertising
-
Salary TBC
-
Associate Medical Director
-
Salary TBC
-
Scientific Team Lead
-
Competitive Salary
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
-
Account Director
-
Negotiable
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Account Director – Global Healthcare PR
-
Salary TBC
- Director Healthcare PR Communications
-
Salary TBC
- Experienced Editor, London, Medical Communications
-
Competitive package
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
Subscribe to our email news alerts
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
Quick links
Infographics
